US pharmaceuticals group has been looking to rebuild its pipeline before crucial cancer drug comes off-patent
These are the stocks posting the largest moves in midday trading.
Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump's planned pharmaceutical tariffs.
Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump's planned pharmaceutical tariffs.
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.
Nominee says he is entitled to 10% of proceeds if case against Merck’s Gardasil treatment succeeds